Soleno Therapeutics (NASDAQ: SLNO) deregisters 3,000,000-share resale after merger
Soleno Therapeutics has filed a post-effective amendment to deregister a 3,000,000-share resale, confirming the termination of the registration following its merger into Neurocrine Biosciences. The amendment addresses an administrative filing error and formally removes all unsold or unissued securities under Registration No. 333-275120 as of May 21, 2026. This action eliminates the registered resale capacity and is a procedural step subsequent to the merger agreement dated April 5, 2026.
Soleno (SLNO) director’s shares cashed out at $53 per-share merger price
Soleno Therapeutics director Matthew Pauls disposed of his equity stake, consisting of 10,491 common shares and a 9,063-share stock option, as part of a merger where Soleno became a wholly owned subsidiary of Neocrine Biosciences. All shares, RSUs, and options were converted into the right to receive $53.00 in cash per share. This transaction was not an open-market sale but rather a standard cash-out process due to the acquisition.
Soleno Therapeutics (Nasdaq:SLNO) - Stock Analysis
This article provides a stock analysis of Soleno Therapeutics (Nasdaq:SLNO), detailing its valuation, future growth prospects, past performance, and financial health. Key recent updates include its acquisition by Neurocrine Biosciences, Inc. for $2.8 billion, a securities class action lawsuit regarding its DCCR program, and various changes in executive leadership and financial forecasts. The company's lead product, VYKAT XR, for Prader-Willi Syndrome, recently received FDA approval and commercial availability.
Soleno Therapeutics (NASDAQ: SLNO) deregisters S-3 after Neurocrine merger
Soleno Therapeutics (NASDAQ: SLNO) has filed a post-effective amendment to deregister all unsold securities previously registered under Form S-3. This action follows the completion of a merger on May 18, 2026, which resulted in Soleno becoming a wholly owned subsidiary of Neurocrine Biosciences, Inc. The deregistration terminates the effectiveness of Registration Statements Nos. 333-275120 and 333-276344, removing any remaining unsold securities.
Soleno Therapeutics (SLNO) CFO has RSUs and stock options cashed out in Neocrine merger
Soleno Therapeutics' CFO, Jennifer Fulk, had her restricted stock units (RSUs) and stock options cashed out as part of Soleno's merger into a wholly owned subsidiary of Neocrine Biosciences. A total of 39,200 RSU shares and an employee stock option covering 67,660 shares were cancelled, with RSU holders receiving $53.00 per share in cash and option holders receiving a cash payment based on the difference between the merger consideration and the exercise price. After these transactions, Fulk holds no remaining equity from these awards.
Soleno Therapeutics (NASDAQ: SLNO) taken private at $53 per share in cash deal
Neurocrine Biosciences has completed its acquisition of Soleno Therapeutics (NASDAQ: SLNO) for $53.00 per share in cash, with approximately 88.9% of shares tendered. Following the tender offer, Soleno merged into Neurocrine's subsidiary on May 18, 2026, becoming a wholly owned subsidiary. As a result, Soleno will be delisted from Nasdaq, deregistered with the SEC, and its previous loan agreement and employee stock purchase plan have been terminated.
Soleno Therapeutics (NASDAQ: SLNO) deregisters S-3 after Neurocrine merger
Soleno Therapeutics (NASDAQ: SLNO) has filed a Post-Effective Amendment to its S-3 registration statements to deregister any unsold securities following its merger with Neurocrine Biosciences, Inc. The deregistration occurred on May 18, 2026, after Soleno became a wholly owned subsidiary of Neurocrine Biosciences, Inc. This action is a routine post-closing administrative step to terminate the effectiveness of the registration statements.
Soleno Therapeutics (SLNO) Nasdaq submits Form 25 to remove common stock
Nasdaq Stock Market LLC has filed a Form 25 to delist Soleno Therapeutics Inc.'s (SLNO) common stock from the exchange and/or withdraw its registration under Section 12(b) of the Exchange Act. This action signifies a formal removal process, although the exact effective date for delisting and subsequent steps for shareholders are not detailed in this filing. The filing indicates compliance with regulatory procedures for delisting, and investors are cautioned that delisting can impact a stock's visibility, trading volume, and price volatility.
Soleno Therapeutics (SLNO) CCO equity cancelled, converted to $53 cash in merger
Soleno Therapeutics' Chief Commercial Officer, Meredith Manning, had her equity holdings, including 64,507 common shares and several employee stock options, cancelled and converted into a cash payment of $53.00 per share. This transaction occurred on May 18, 2026, as part of Soleno's merger with Neurocrine Biosciences. The Form 4 filing confirms that all of Manning's reported equity awards in Soleno were disposed of back to the issuer, reflecting the change from equity to cash consideration following the merger.
Soleno Therapeutics (SLNO) CBO equity canceled, cashed out at $53 per share
Soleno Therapeutics' Chief Business Officer, Kevin Norrett, cashed out his equity holdings, including RSUs and stock options, as part of the company's merger with Neocrine Biosciences. All holdings were converted into cash at a rate of $53.00 per share, resulting in Norrett holding no direct shares or options after the transactions. The transaction details were reported in a Form 4 SEC filing, outlining the disposition of 17,786 RSU-based shares and two stock option grants totaling 68,286 shares.
Soleno Therapeutics (SLNO) CDO equity cancelled for $53 cash in merger
Soleno Therapeutics' Chief Development Officer, Manher Joshi, disposed of all his equity holdings, including restricted stock units and stock options, as part of Soleno's merger into Neurocrine Biosciences. These holdings were cancelled and converted into a cash payment of $53.00 per share. Following these transactions, Joshi holds no remaining common stock or options in Soleno Therapeutics.
Soleno Therapeutics (SLNO) CEO fully cashed out as $53-per-share merger closes
Soleno Therapeutics CEO Anish Bhatnagar disposed of all his company equity, including common shares, RSUs, and stock options, in connection with Soleno's cash merger with Neocrine Biosciences. The transactions occurred on May 18, 2026, where all equity was converted into cash at a fixed $53.00 per share merger consideration. This Form 4 filing confirms the completion of the cash-out and indicates Bhatnagar holds zero remaining Soleno shares or options, as the company is now a wholly-owned subsidiary of Neocrine Biosciences.
Soleno (SLNO) director’s 10,046 RSUs canceled for $53 cash in merger
Soleno Therapeutics director Mark W. Hahn reported the disposition of 10,046 restricted stock units (RSUs) that were canceled as part of a merger where Soleno became a wholly owned subsidiary of Neocrine Biosciences, Inc. Each RSU was converted into the right to receive $53.00 in cash. Following this transaction, Hahn holds no direct shares of Soleno common stock.
Soleno Therapeutics (SLNO) director exits as $53-per-share cash merger closes
Soleno Therapeutics director Dawn Carter reported a disposition of 16,991 shares of Common Stock in connection with the company’s acquisition by Neocrine Biosciences, Inc. through its subsidiary Sigma Merger Sub, Inc. The merger, which occurred on May 18, 2026, resulted in each outstanding share and restricted stock unit being cancelled and converted into the right to receive $53.00 in cash. Following this transaction, Carter no longer holds any Soleno shares.
Neurocrine (SLNO) completes tender offer; ~46.36M Soleno shares tendered
Neurocrine Biosciences completed its acquisition of Soleno Therapeutics, with approximately 88.9% of Soleno's outstanding common stock (46.36 million shares) tendered at $53.00 per share. The tender offer closed on May 15, 2026, with Neurocrine accepting the shares on May 17, 2026, leading to a merger where Soleno became a wholly-owned subsidiary. Plans are underway to delist Soleno shares from Nasdaq and terminate its reporting obligations.
Soleno Therapeutics, Inc.(NasdaqCM:SLNO) dropped from S&P Biotechnology Select Industry Index
Soleno Therapeutics, Inc. (NasdaqCM:SLNO) has been removed from the S&P Biotechnology Select Industry Index. This news follows a period of significant activity for the company, including an earnings report for the first quarter ended March 31, 2026, and several analyst downgrades with adjusted price targets. The company is focused on developing therapeutics for rare diseases, with its primary product VYKAT XR for Prader-Willi syndrome.
Avoro and Aghazadeh report 4.45% stake in Soleno (NASDAQ: SLNO)
Avoro Capital Advisors LLC and Behzad Aghazadeh have each reported a beneficial ownership of 2,300,000 shares of Soleno Therapeutics (NASDAQ: SLNO), representing a 4.45% stake in the company. This disclosure was made via an amended Schedule 13G/A filing with the SEC, indicating the shares were acquired for investment purposes. The percentage is based on 51,718,149 shares outstanding as of March 31, 2026, with both parties having sole voting and dispositive power over their respective shares.
Wellington affiliates disclose 8.57% stake in Soleno Therapeutics (SLNO)
Wellington Management Group LLP and its affiliated entities have reported a beneficial ownership of 8.57% in Soleno Therapeutics (SLNO), comprising 4,426,781 shares. This updated disclosure, filed as a Schedule 13G/A, indicates a passive investment where shares are held for clients of multiple Wellington investment advisers, with shared voting and dispositive powers. The filing emphasizes that this is an institutional disclosure, not signaling direct corporate control.
State Street (SLNO) holds 2.68M shares, 5.2% stake in Soleno Therapeutics
State Street Corporation has disclosed a beneficial ownership of 2,680,802 shares in Soleno Therapeutics Inc. (SLNO), representing a 5.2% stake as of March 31, 2026. This Schedule 13G filing indicates that State Street holds shared voting and dispositive power over these shares, with no sole control by any single entity. The filing outlines the various State Street adviser entities involved in this investment.
SLNO 8-DAY DEADLINE ALERT: Hagens Berman Alerts Soleno Therapeutics (SLNO) Investors to Securities Class Action Alleging Hyperphagia Drug Launch Disruptions - Hagens Berman
Hagens Berman has alerted investors in Soleno Therapeutics (SLNO) about a pending securities class action lawsuit, with a lead plaintiff deadline of May 5, 2026. The lawsuit alleges that Soleno misrepresented the safety, efficacy, and commercial viability of its drug VYKAT™ XR for Prader-Willi syndrome, including downplaying safety concerns and inflating launch metrics. These alleged misrepresentations led to significant stock declines following reports from an activist short seller and lower-than-expected Q3 2025 financial results.
Soleno Therapeutics faces final earnings test before buyout By Investing.com
Soleno Therapeutics is preparing to report its final earnings as an independent company before its acquisition by Neurocrine Biosciences for $53 per share. Analysts are looking closely at the performance of Vykat XR, the company's Prader-Willi syndrome treatment, given previous questions about management's confidence and the drug's blockbuster potential. While the stock now trades near the acquisition price, the earnings report will offer insight into the drug's commercial trajectory and adoption rates.
Soleno Therapeutics faces final earnings test before buyout
Soleno Therapeutics is reporting its first-quarter earnings, likely its last as an independent company, before its acquisition by Neurocrine Biosciences for $53 per share. Analysts are closely watching Vykat XR revenue figures to gauge the drug's continued success and whether the acquisition price adequately values its potential. The market expects earnings of $0.68 per share on revenue of $93.78 million, with preliminary product revenue already indicating continued sequential growth.
Number of shareholders of Soleno Therapeutics, Inc. – NASDAQ:SLNO
This article provides financial information for Soleno Therapeutics, Inc. (NASDAQ: SLNO). It lists the stock ticker, market, and offers an overview of financials, news, and other data for the company. The main focus is on the number of shareholders, though the specific value is not directly visible in the provided text.
Soleno Therapeutics (SLNO) Q4 Profitability Jump Tests Longstanding Bearish Earnings Narratives
Soleno Therapeutics (SLNO) reported a significant swing to profitability in Q4 2025, with revenue of US$91.7 million and EPS of US$0.81, marking a clear departure from previous losses. The article discusses how this rapid shift challenges historical bearish earnings narratives, highlighting the tension between the company's high P/E ratio and strong growth forecasts versus past losses and potential future risks. It suggests further analysis is needed to assess the durability of this newfound profitability.
Soleno Therapeutics (SLNO) Q4 Profitability Jump Tests Longstanding Bearish Earnings Narratives
Soleno Therapeutics (SLNO) reported a significant swing to profitability in Q4 2025, with revenue reaching US$91.7 million and basic EPS of US$0.81, marking a clear turnaround from previous quarterly losses. This rapid shift challenges long-standing bearish narratives, though a high P/E ratio and past losses introduce caution. Investors are urged to examine growth, risks, and valuation beyond the headlines.
Soleno Therapeutics (SLNO) Q4 Profitability Jump Tests Longstanding Bearish Earnings Narratives
Soleno Therapeutics (SLNO) reported a significant swing to profitability in Q4 2025, with revenue of US$91.7 million and basic EPS of US$0.81, marking a clear departure from previous quarterly losses. This sharp turnaround challenges long-standing bearish narratives, though the company's high P/E ratio and historical losses still present mixed signals for investors. Both bullish and bearish cases are discussed, highlighting the tension between rapid growth and the durability of this newfound profitability.
A Look At Soleno Therapeutics (SLNO) Valuation After Recent Share Momentum And VYKAT XR Launch Progress
Soleno Therapeutics (SLNO) has seen significant recent share momentum, with a one-month return of 34.01% and a three-month return of 25.64%. The company's valuation is debated, with one narrative suggesting it's 53.4% undervalued with a fair value of $113.54 due to the rapid uptake of VYKAT XR, while another view points to its high P/E ratio of 133.7x as a sign of overvaluation compared to industry averages. Investors are advised to review all data to determine if a buying opportunity exists or if the market has already factored in future growth.
Is It Time To Reassess Soleno Therapeutics (SLNO) After A 10x Three Year Surge?
Soleno Therapeutics (SLNO) has seen significant gains over three years, with a mixed performance recently. A Discounted Cash Flow (DCF) analysis suggests the stock is undervalued by 88.0% at its current price of US$52.94, while a Price-to-Earnings (P/E) ratio comparison indicates it's overvalued compared to its industry and fair ratio. The article encourages investors to consider different valuation narratives and personalize their assumptions.
Is It Time To Reassess Soleno Therapeutics (SLNO) After A 10x Three Year Surge?
Soleno Therapeutics (SLNO) has seen significant price swings, including a 10x surge over three years and a 29.1% decline in the last year. Simply Wall St's analysis presents a mixed valuation; a Discounted Cash Flow (DCF) model suggests the stock is undervalued by 88.0% with an intrinsic value of $442.21, while a Price-to-Earnings (P/E) comparison indicates it is overvalued at 133.7x against a "Fair Ratio" of 25.8x.
Janus Henderson Group (SLNO) reports 1.21M-share, 2.3% position
Janus Henderson Group plc has disclosed a 2.3% beneficial ownership stake in Soleno Therapeutics, Inc., amounting to 1,205,303 common shares as of April 30, 2026. This position is held by multiple Janus Henderson asset managers who exercise shared voting and dispositive power on behalf of managed portfolios. The filing clarifies that while the asset managers control investment and voting discretion, they disclaim rights to dividends or sale proceeds, which accrue to the managed portfolios.
FMR LLC amends 13G/A: Soleno Therapeutics (NASDAQ: SLNO) 0.4% stake
FMR LLC has filed an amendment to its Schedule 13G/A, reporting a beneficial ownership of 193,013.61 shares, or 0.4%, of Soleno Therapeutics (NASDAQ: SLNO) common stock as of April 30, 2026. This filing indicates a passive investment stance by the large investment manager. Abigail P. Johnson is also listed with dispositive power over the same number of shares.
FMR LLC increases reported stake in Soleno Therapeutics (NASDAQ: SLNO)
FMR LLC has filed an Amendment No. 2 to a Schedule 13G/A, reporting beneficial ownership of 5,768,409.61 shares of Soleno Therapeutics Inc. (NASDAQ: SLNO) common stock, which represents an 11.2% stake in the company. The filing details FMR LLC's sole voting power over 5,583,298 shares and sole dispositive power over the full beneficial ownership amount. This amendment clarifies the institutional holding and associated powers within FMR LLC and for Abigail P. Johnson.
A Look At Soleno Therapeutics (SLNO) Valuation After Recent Share Momentum And VYKAT XR Launch Progress
Soleno Therapeutics (SLNO) has seen significant recent share momentum, though its one-year return remains negative. While analysts see the stock as undervalued with a fair value of $113.54 due to the successful launch of VYKAT XR, its high P/E ratio of 133.7x suggests potential valuation risk compared to the biotech industry average. Investors are advised to review various data and warning signs to form their own conclusions.
SOLENO DEADLINE TODAY: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Soleno Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SLNO
Rosen Law Firm is reminding investors who purchased Soleno Therapeutics, Inc. (NASDAQ: SLNO) common stock between March 26, 2025, and November 4, 2025, of the May 5, 2026, lead plaintiff deadline in a securities class action lawsuit. The lawsuit alleges that Soleno Therapeutics made false or misleading statements regarding safety concerns and commercial viability of their drug DCCR for Prader-Willi syndrome. Investors are encouraged to contact Rosen Law Firm for information on joining the lawsuit.
SOLENO THERAPEUTICS DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Soleno Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SLNO
Rosen Law Firm is reminding investors of Soleno Therapeutics, Inc. (NASDAQ: SLNO) who purchased common stock between March 26, 2025, and November 4, 2025, about the May 5, 2026 lead plaintiff deadline for a securities class action lawsuit. The lawsuit alleges that Soleno misrepresented safety concerns related to its DCCR clinical trial program for Prader-Willi syndrome, implying greater safety risks and lower commercial viability than disclosed. Investors are encouraged to contact Rosen Law Firm to join the class action and learn about their rights.
SLNO DEADLINE ALERT: Hagens Berman Alerts Soleno Therapeutics (SLNO) Investors to Today's Lead Plaintiff Deadline in Securities Class Action
Hagens Berman is alerting investors in Soleno Therapeutics (NASDAQ: SLNO) about an upcoming lead plaintiff deadline in a securities class action lawsuit. The lawsuit alleges that Soleno misrepresented the safety and commercial viability of its drug VYKAT™ XR for Prader-Willi syndrome, concealing safety risks and inflating launch metrics. Investors who purchased Soleno stock between March 26, 2025, and November 4, 2025, are urged to submit their losses by May 5, 2026.
Soleno Therapeutics, Inc. Notice of May 5, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
Kahn Swick & Foti, LLC (KSF) has notified investors of Soleno Therapeutics, Inc. (SLNO) about a class action securities lawsuit. The lawsuit alleges that Soleno and its executives failed to disclose potential safety concerns related to its DCCR Phase 3 clinical trial program and its commercial viability, particularly regarding excessive fluid retention. The deadline for investors to request lead plaintiff status is May 5, 2026, and KSF is encouraging affected investors to contact their firm.
SLNO Shareholder Alert: Soleno Therapeutics, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact The Gross Law Firm
The Gross Law Firm has issued a shareholder alert for Soleno Therapeutics, Inc. (NASDAQ: SLNO) concerning a securities class action lawsuit. The lawsuit alleges that Soleno Therapeutics made materially false and/or misleading statements regarding safety concerns and commercial viability of its drug DCCR during its Phase 3 clinical trial. Investors who purchased SLNO shares between March 26, 2025, and November 4, 2025, are encouraged to contact the firm by the May 5, 2026 deadline to potentially be appointed as lead plaintiff.
SLNO Shareholder Alert: Soleno Therapeutics, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact The Gross Law Firm
The Gross Law Firm has issued a shareholder alert regarding a securities class action lawsuit against Soleno Therapeutics, Inc. (NASDAQ: SLNO). The lawsuit alleges that Soleno Therapeutics made materially false and misleading statements concerning safety concerns related to its product, DCCR, during its Phase 3 clinical trial, impacting its commercial viability. Investors who purchased shares between March 26, 2025, and November 4, 2025, are encouraged to contact the firm by May 5, 2026, to discuss potential lead plaintiff appointment.
Portnoy Law Firm Announces Class Action on Behalf of Soleno Therapeutics, Inc. Investors
The Portnoy Law Firm has announced a class action lawsuit against Soleno Therapeutics, Inc. (NASDAQ: SLNO) on behalf of investors who purchased securities between March 6, 2025, and November 4, 2025. The lawsuit alleges that Soleno concealed significant safety evidence related to "excess fluid retention" in its lead drug, DCCR, for Prader-Willi syndrome, leading to stock price declines after a patient death and a critical report by Scorpion Capital. Investors are encouraged to contact the firm to discuss their legal rights.
SLNO DEADLINE ALERT: Hagens Berman Alerts Soleno Therapeutics (SLNO) Investors to Today's Lead Plaintiff Deadline in Securities Class Action
Hagens Berman is alerting investors of Soleno Therapeutics (SLNO) to a lead plaintiff deadline today, May 5, 2026, in a securities class action lawsuit. The lawsuit alleges that Soleno misrepresented the safety and commercial viability of its drug VYKAT™ XR for Prader-Willi syndrome by concealing safety concerns and inflating launch metrics. Investors who purchased Soleno stock between March 26, 2025, and November 4, 2025, and suffered losses are encouraged to submit their information.
SOLENO THERAPEUTICS DEADLINE TOMORROW: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Soleno Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SLNO
This article is an alert from Rosen, Global Investor Counsel, encouraging investors of Soleno Therapeutics, Inc. (SLNO) to secure counsel before an important deadline in a securities class action. The full content of the article, which appears to be a stub or an error, is primarily navigation and boilerplate website information from a site named "Scott Coop - Stock Quotes," rather than detailed information about the class action itself.
SLNO Deadline: SLNO Investors Have Opportunity to Lead Soleno Therapeutics, Inc. Securities Fraud Lawsuit
The Rosen Law Firm reminds Soleno Therapeutics, Inc. (NASDAQ: SLNO) investors of the May 5, 2026, lead plaintiff deadline in a securities fraud lawsuit. The lawsuit alleges that Soleno made misleading statements regarding systemic safety concerns related to its DCCR clinical trial program for Prader-Willi syndrome. Investors who purchased Soleno common stock between March 26, 2025, and November 4, 2025, may be entitled to compensation.
SOLENO THERAPEUTICS DEADLINE TOMORROW: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Soleno Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SLNO
Rosen Law Firm is reminding investors of Soleno Therapeutics, Inc. (NASDAQ: SLNO) that the lead plaintiff deadline for a securities class action lawsuit is May 5, 2026. The lawsuit alleges that Soleno made false or misleading statements regarding the safety risks and commercial viability of its DCCR Prader-Willi syndrome treatment. Investors who purchased Soleno common stock during the Class Period (March 26, 2025, to November 4, 2025) are encouraged to contact Rosen Law Firm for information on joining the class action.
SOLENO THERAPEUTICS CLASS ACTION DEADLINE TOMORROW: Bragar
Bragar Eagel & Squire, P.C. has filed a class action lawsuit against Soleno Therapeutics, Inc. (NASDAQ: SLNO) on behalf of investors who purchased shares between March 26, 2025, and November 4, 2025. The lawsuit alleges that Soleno misrepresented safety concerns related to its DCCR clinical trial program. Investors have until May 5, 2026, to apply to be appointed as lead plaintiff.
SLNO Deadline: SLNO Investors Have Opportunity to Lead Soleno Therapeutics, Inc. Securities Fraud Lawsuit
The Rosen Law Firm reminds investors who purchased Soleno Therapeutics, Inc. (NASDAQ: SLNO) common stock between March 26, 2025, and November 4, 2025, of the May 5, 2026 lead plaintiff deadline for a securities fraud lawsuit. The lawsuit alleges that Soleno made false or misleading statements regarding safety concerns and commercial viability of its DCCR treatment for Prader-Willi syndrome. Investors impacted during this period are encouraged to join the class action to potentially recover losses.
SLNO Deadline: SLNO Investors Have Opportunity to Lead Soleno Therapeutics, Inc. Securities Fraud Lawsuit
Rosen Law Firm is reminding purchasers of Soleno Therapeutics, Inc. (NASDAQ: SLNO) common stock during the Class Period (March 26, 2025, to November 4, 2025) of the May 5, 2026, lead plaintiff deadline for a securities fraud lawsuit. Investors who bought SLNO stock during this period have the opportunity to lead the lawsuit. The announcement emphasizes the approaching deadline for affected investors.
Deadline Soon: Soleno Therapeutics, Inc. (SLNO) Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
The Law Offices of Frank R. Cruz is urging Soleno Therapeutics, Inc. (SLNO) shareholders who lost money to join a securities fraud class action lawsuit, with a deadline of May 5, 2026, to participate as a lead plaintiff. The lawsuit alleges that Soleno made materially false and misleading statements and failed to disclose significant safety concerns related to its drug DCCR, which led to substantial stock price declines following multiple negative reports and financial disclosures. Investors who purchased SLNO common stock between March 26, 2025, and November 4, 2026, are encouraged to contact the firm for more information.
SLNO Investors Have Opportunity to Lead Soleno Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm has announced a class action lawsuit against Soleno Therapeutics, Inc. (NASDAQ: SLNO) for alleged securities fraud, covering investors who purchased securities between March 26, 2025, and November 4, 2025. The lawsuit claims Soleno made misleading statements regarding safety concerns with its DCCR treatment, which reportedly had higher safety risks and lower commercial viability than disclosed. Investors affected are encouraged to contact the firm by May 5, 2026, to discuss their rights.
SLNO Investors Have Opportunity to Lead Soleno Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm has announced a class action lawsuit against Soleno Therapeutics, Inc. (NASDAQ: SLNO) for alleged securities fraud. Investors who purchased Soleno securities between March 26, 2025, and November 4, 2025, are encouraged to contact the firm by May 5, 2026. The lawsuit claims Soleno made false and misleading statements regarding safety concerns and commercial viability of its DCCR treatment during its Phase 3 clinical trial.
